Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
374 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Atopic Dermatitis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis - Pipeline Review, H1 2017, provides an overview of the Atopic Dermatitis (Dermatology) pipeline landscape. Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Atopic Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 40, 21, 1, 44, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 2 and 2 molecules, respectively. Atopic Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Dermatology). - The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Atopic Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Atopic Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Atopic Dermatitis - Overview 12 Atopic Dermatitis - Therapeutics Development 13 Pipeline Overview 13 Pipeline by Companies 14 Pipeline by Universities/Institutes 20 Products under Development by Companies 21 Products under Development by Universities/Institutes 28 Atopic Dermatitis - Therapeutics Assessment 29 Assessment by Target 29 Assessment by Mechanism of Action 33 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Atopic Dermatitis - Companies Involved in Therapeutics Development 41 AbbVie Inc 41 Accolade Pharmaceuticals LLC 41 Albireo Pharma Inc 42 Almirall SA 42 Amgen Inc 43 Amorepacific Corp 43 AnaptysBio Inc 44 AnGes MG Inc 44 Antibiotx ApS 45 Avexxin AS 45 Blueberry Therapeutics Ltd 46 Brickell Biotech Inc 46 Celgene Corp 47 Cell Medica Ltd 47 Cellceutix Corp 48 ChemoCentryx Inc 48 ChironWells GmbH 49 Chugai Pharmaceutical Co Ltd 49 Clevexel Pharma SA 50 Curapel Ltd 50 Cutanea Life Sciences Inc 51 Dermala Inc 51 Dr. August Wolff GmbH & Co KG Arzneimittle 52 Eli Lilly and Company 52 Exicure Inc 53 F. Hoffmann-La Roche Ltd 53 Foamix Pharmaceuticals Ltd 54 Fountain Biopharma Inc 54 Galapagos NV 55 Galectin Therapeutics Inc 55 GlaxoSmithKline Plc 56 Glenmark Pharmaceuticals Ltd 56 Grupo Ferrer Internacional SA 57 GTx Inc 57 Han Wha Pharma Co Ltd 58 HanAll Biopharma Co Ltd 58 Heptares Therapeutics Ltd 59 Herantis Pharma Plc 59 iCo Therapeutics Inc. 60 Immune Pharmaceuticals Inc 60 Incyte Corp 61 Inflamalps SA 61 Japan Tobacco Inc 62 Kang Stem Biotech Co Ltd 62 KPI Therapeutics Inc 63 LEO Pharma A/S 63 Madam Therapeutics BV 64 MedImmune LLC 64 NeoPharm Co Ltd 65 Novan Inc 65 Novartis AG 66 Orbis Biosciences Inc 66 Otsuka Holdings Co Ltd 67 Oxagen Ltd 67 Pfizer Inc 68 Pharis Biotec GmbH 68 Pharmedartis GmbH 69 Provectus Biopharmaceuticals Inc 69 Qurient Co Ltd 70 Realm Therapeutics Plc 70 Regeneron Pharmaceuticals Inc 71 Roivant Sciences Ltd 71 Signum Biosciences Inc 72 Signum Dermalogix Inc 72 Spherium Biomed SL 73 sterna biologicals Gmbh & Co KG 73 Sun Pharma Advanced Research Company Ltd 74 SWITCH Biotech LLC 74 Thesan Pharmaceuticals Inc 75 Torrent Pharmaceuticals Ltd 75 Trevi Therapeutics Inc 76 Valeant Pharmaceuticals International Inc 76 Vicore Pharma AB 77 Vitae Pharmaceuticals Inc 77 VivaCell Biotechnology Espana SL 78 Xencor Inc 78 Zhejiang I-Biological Technology Co Ltd 79 Atopic Dermatitis - Drug Profiles 80 A-3914 - Drug Profile 80 A-5425 - Drug Profile 81 AKP-11 - Drug Profile 82 Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile 84 ALX-101 - Drug Profile 85 AMG-0101 - Drug Profile 86 Anatabine - Drug Profile 88 ANB-020 - Drug Profile 91 Antisense Oligonucleotide to Antagonize IL-4RA for Atopic Dermatitis - Drug Profile 93 apremilast - Drug Profile 94 Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile 106 ARN-077 - Drug Profile 107 AVX-001 - Drug Profile 108 AZT-01 - Drug Profile 110 B-244 - Drug Profile 111 baricitinib - Drug Profile 113 BB-2702 - Drug Profile 123 BBI-2000 - Drug Profile 124 BBI-5000 - Drug Profile 125 bertilimumab - Drug Profile 126 betamethasone valerate - Drug Profile 130 Biologic for Atopic Dermatitis - Drug Profile 131 Biologic for Atopic Dermatitis and Eczema - Drug Profile 132 brilacidin tetrahydrochloride - Drug Profile 133 BTX-1204 - Drug Profile 144 C-21 - Drug Profile 145 CBP-174 - Drug Profile 148 CBP-201 - Drug Profile 149 CCX-6239 - Drug Profile 150 CDE-001 - Drug Profile 151 Cis-Urocanic Acid - Drug Profile 152 cobamamide - Drug Profile 154 CT-101 - Drug Profile 156 CT-103 - Drug Profile 157 CVXL-0074 - Drug Profile 158 cyclosporin - Drug Profile 159 cyclosporine - Drug Profile 160 dalazatide - Drug Profile 161 DMT-210 - Drug Profile 166 Drug for Atopic Dermatitis - Drug Profile 168 Drug for Atopic Dermatitis - Drug Profile 169 dupilumab - Drug Profile 170 FB-825 - Drug Profile 179 fevipiprant - Drug Profile 180 FIB-116 - Drug Profile 182 FM-1202 - Drug Profile 183 Furestem-AD - Drug Profile 184 GBR-830 - Drug Profile 185 GLPG-2534 - Drug Profile 186 GRMD-02 - Drug Profile 187 GSK-3772847A - Drug Profile 200 Gtx-186 - Drug Profile 201 Histimex - Drug Profile 202 house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile 203 HS-378 - Drug Profile 204 IDP-124 - Drug Profile 205 INV-25 - Drug Profile 206 INV-88 - Drug Profile 207 JTE-052 - Drug Profile 208 K-1032 - Drug Profile 209 KPI-150 - Drug Profile 210 lebrikizumab - Drug Profile 211 LEKTI-6 - Drug Profile 215 LP-0058 - Drug Profile 216 LP-0108 - Drug Profile 217 LP-0145 - Drug Profile 218 LP-0155 - Drug Profile 219 MEDI-9314 - Drug Profile 220 mepolizumab - Drug Profile 221 MLR-1130 - Drug Profile 227 mometasone furoate - Drug Profile 228 Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile 229 Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 230 MOR-106 - Drug Profile 231 MSB-01 - Drug Profile 233 nalbuphine hydrochloride ER - Drug Profile 234 nemolizumab - Drug Profile 238 niclosamide - Drug Profile 240 NPB-311 - Drug Profile 242 NPH-12 - Drug Profile 243 OC-2417 - Drug Profile 244 octenidine hydrochloride - Drug Profile 245 OLX-103 - Drug Profile 246 omiganan pentahydrochloride - Drug Profile 247 OPA-15406 - Drug Profile 250 P-10 - Drug Profile 252 P-148 - Drug Profile 253 PAC-14028 - Drug Profile 254 Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile 256 Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 257 PF-04965842 - Drug Profile 258 PF-06817024 - Drug Profile 259 PH-10 - Drug Profile 260 PL-601 - Drug Profile 263 PMA-101R - Drug Profile 264 PMA-201 - Drug Profile 265 PMA-411R - Drug Profile 266 PR-022 - Drug Profile 267 prednisone - Drug Profile 269 PZ-235 - Drug Profile 270 ruxolitinib phosphate - Drug Profile 271 RVT-201 - Drug Profile 286 RVT-501 - Drug Profile 287 SB-011 - Drug Profile 289 SB-414 - Drug Profile 290 secukinumab - Drug Profile 291 SIG-1322 - Drug Profile 305 SIG-1451 - Drug Profile 306 Small Molecule for Atopic Dermatitis - Drug Profile 307 Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile 308 Small Molecules for Atopic Dermatitis - Drug Profile 309 Small Molecules for Atopic Dermatitis - Drug Profile 310 Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile 311 SNA-120 - Drug Profile 312 SNA-125 - Drug Profile 315 SUN-0597 - Drug Profile 316 SWT-01113 - Drug Profile 318 SWT-05141 - Drug Profile 319 Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile 320 tacrolimus - Drug Profile 321 tezepelumab - Drug Profile 322 tralokinumab - Drug Profile 324 upadacitinib tartrate - Drug Profile 327 VTP-38543 - Drug Profile 330 WBI-1001 - Drug Profile 332 WOL-071007 - Drug Profile 334 XmAb-7195 - Drug Profile 335 YJC-10592 - Drug Profile 337 Zafi-1 - Drug Profile 338 zafirlukast - Drug Profile 339 zileuton - Drug Profile 340 ZPL-389 - Drug Profile 341 ZPL-521 - Drug Profile 343 Atopic Dermatitis - Dormant Projects 344 Atopic Dermatitis - Discontinued Products 350 Atopic Dermatitis - Product Development Milestones 351 Featured News & Press Releases 351 Appendix 364 Methodology 364 Coverage 364 Secondary Research 364 Primary Research 364 Expert Panel Validation 364 Contact Us 364 Disclaimer 365
List of Tables
Number of Products under Development for Atopic Dermatitis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Atopic Dermatitis - Pipeline by AbbVie Inc, H1 2017 Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals LLC, H1 2017 Atopic Dermatitis - Pipeline by Albireo Pharma Inc, H1 2017 Atopic Dermatitis - Pipeline by Almirall SA, H1 2017 Atopic Dermatitis - Pipeline by Amgen Inc, H1 2017 Atopic Dermatitis - Pipeline by Amorepacific Corp, H1 2017 Atopic Dermatitis - Pipeline by AnaptysBio Inc, H1 2017 Atopic Dermatitis - Pipeline by AnGes MG Inc, H1 2017 Atopic Dermatitis - Pipeline by Antibiotx ApS, H1 2017 Atopic Dermatitis - Pipeline by Avexxin AS, H1 2017 Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H1 2017 Atopic Dermatitis - Pipeline by Brickell Biotech Inc, H1 2017 Atopic Dermatitis - Pipeline by Celgene Corp, H1 2017 Atopic Dermatitis - Pipeline by Cell Medica Ltd, H1 2017 Atopic Dermatitis - Pipeline by Cellceutix Corp, H1 2017 Atopic Dermatitis - Pipeline by ChemoCentryx Inc, H1 2017 Atopic Dermatitis - Pipeline by ChironWells GmbH, H1 2017 Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017 Atopic Dermatitis - Pipeline by Clevexel Pharma SA, H1 2017 Atopic Dermatitis - Pipeline by Curapel Ltd, H1 2017 Atopic Dermatitis - Pipeline by Cutanea Life Sciences Inc, H1 2017 Atopic Dermatitis - Pipeline by Dermala Inc, H1 2017 Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H1 2017 Atopic Dermatitis - Pipeline by Eli Lilly and Company, H1 2017 Atopic Dermatitis - Pipeline by Exicure Inc, H1 2017 Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017 Atopic Dermatitis - Pipeline by Fountain Biopharma Inc, H1 2017 Atopic Dermatitis - Pipeline by Galapagos NV, H1 2017 Atopic Dermatitis - Pipeline by Galectin Therapeutics Inc, H1 2017 Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H1 2017 Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017 Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional SA, H1 2017 Atopic Dermatitis - Pipeline by GTx Inc, H1 2017 Atopic Dermatitis - Pipeline by Han Wha Pharma Co Ltd, H1 2017 Atopic Dermatitis - Pipeline by HanAll Biopharma Co Ltd, H1 2017 Atopic Dermatitis - Pipeline by Heptares Therapeutics Ltd, H1 2017 Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H1 2017 Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H1 2017 Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc, H1 2017 Atopic Dermatitis - Pipeline by Incyte Corp, H1 2017 Atopic Dermatitis - Pipeline by Inflamalps SA, H1 2017 Atopic Dermatitis - Pipeline by Japan Tobacco Inc, H1 2017 Atopic Dermatitis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017 Atopic Dermatitis - Pipeline by KPI Therapeutics Inc, H1 2017 Atopic Dermatitis - Pipeline by LEO Pharma A/S, H1 2017 Atopic Dermatitis - Pipeline by Madam Therapeutics BV, H1 2017 Atopic Dermatitis - Pipeline by MedImmune LLC, H1 2017 Atopic Dermatitis - Pipeline by NeoPharm Co Ltd, H1 2017 Atopic Dermatitis - Pipeline by Novan Inc, H1 2017 Atopic Dermatitis - Pipeline by Novartis AG, H1 2017 Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H1 2017 Atopic Dermatitis - Pipeline by Otsuka Holdings Co Ltd, H1 2017 Atopic Dermatitis - Pipeline by Oxagen Ltd, H1 2017 Atopic Dermatitis - Pipeline by Pfizer Inc, H1 2017 Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H1 2017 Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H1 2017 Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017 Atopic Dermatitis - Pipeline by Qurient Co Ltd, H1 2017 Atopic Dermatitis - Pipeline by Realm Therapeutics Plc, H1 2017 Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017 Atopic Dermatitis - Pipeline by Roivant Sciences Ltd, H1 2017 Atopic Dermatitis - Pipeline by Signum Biosciences Inc, H1 2017 Atopic Dermatitis - Pipeline by Signum Dermalogix Inc, H1 2017 Atopic Dermatitis - Pipeline by Spherium Biomed SL, H1 2017 Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H1 2017 Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H1 2017 Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals Inc, H1 2017 Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017 Atopic Dermatitis - Pipeline by Trevi Therapeutics Inc, H1 2017 Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017 Atopic Dermatitis - Pipeline by Vicore Pharma AB, H1 2017 Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals Inc, H1 2017 Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana SL, H1 2017 Atopic Dermatitis - Pipeline by Xencor Inc, H1 2017 Atopic Dermatitis - Pipeline by Zhejiang I-Biological Technology Co Ltd, H1 2017 Atopic Dermatitis - Dormant Projects, H1 2017 Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..1), H1 2017 Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..2), H1 2017 Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..3), H1 2017 Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..4), H1 2017 Atopic Dermatitis - Dormant Projects, H1 2017 (Contd..5), H1 2017 Atopic Dermatitis - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
